Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 | P30556 | 14/20 | 0.62 |
| ▸ | LTB4R2 | Q9NPC1 | 5/20 | 0.62 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.62 |
| ▸ | GP6 | Q9HCN6 | 1/20 | 0.62 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.44 |
| ▸ | AGT | P01019 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28455049 | 1.00 | AGTR1 (0.62) | AGTR1LTB4R2ABCB11GP6AGTR2 | |
| SCHEMBL1891052 | 1.00 | AGTR1 (0.62) | AGTR1LTB4R2ABCB11GP6AGTR2 | |
| SCHEMBL8140438 | 0.94 | AGTR1 (0.56) | AGTR1LTB4R2ABCB11GP6AGTR2 | |
| SCHEMBL5180024 | 0.93 | AGTR1 (0.53) | AGTR1LTB4R2ABCB11GP6AGTR2 | |
| SCHEMBL5591584 | 0.93 | AGTR1 (0.53) | AGTR1LTB4R2ABCB11GP6AGTR2 | |
| SCHEMBL29670077 | 0.92 | AGTR1 (0.63) | AGTR1LTB4R2ABCB11GP6AGTR2 | |
| SCHEMBL1259493 | 0.92 | AGTR1 (0.63) | AGTR1LTB4R2ABCB11GP6AGTR2 | |
| SCHEMBL2443650 | 0.92 | AGTR1 (0.63) | AGTR1LTB4R2ABCB11GP6AGTR2 | |
| SCHEMBL10109393 | 0.92 | AGTR1 (0.64) | AGTR1LTB4R2ABCB11GP6 | |
| SCHEMBL13495677 | 0.92 | AGTR1 (0.61) | AGTR1LTB4R2ABCB11GP6AGTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112641773-A | Composition containing heterocyclic compound and use thereof | 黄泳华 | 2021-04-13 | — | — | CN | claimed |
| CN-111265518-A | Composition containing a mixture of biphenyl derivatives and uses thereof | 黄泳华 | 2020-06-12 | — | — | CN | claimed |
| US-20070117987-A1 | Process for preparing valsartan | TEVA PHARMACEUTICALS USA, INC. | 2007-05-24 | — | — | US | claimed |
| CN-112641773-A | Composition containing heterocyclic compound and use thereof | 黄泳华 | 2021-04-13 | — | — | CN | disclosed |
| CN-111265518-A | Composition containing a mixture of biphenyl derivatives and uses thereof | 黄泳华 | 2020-06-12 | — | — | CN | disclosed |
| EP-1831186-B1 | A PROCESS FOR THE SYNTHESIS OF VALSARTAN | KRKA D D NOVO MESTO (SI) | 2010-07-28 | — | — | EP | disclosed |
| EP-1812411-A2 | PROCESS FOR PREPARING VALSARTAN | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2007-08-01 | — | — | EP | disclosed |
| US-20070117987-A1 | Process for preparing valsartan | TEVA PHARMACEUTICALS USA, INC. | 2007-05-24 | — | — | US | disclosed |
| WO-2007005967-A2 | PROCESS FOR PREPARING VALSARTAN | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2007-01-11 | — | — | WO | disclosed |
| EP-1661891-A1 | A process for the synthesis of valsartan | KRKA, D.D., Novo Mesto (SI) | 2006-05-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070117987-A1 | Process for preparing valsartan | REN, PREP, AVPR2 | AGTR1 16/4885LTB4R2 2868/4885ABCB11 1114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.